With paltusotine, we’re developing a once-daily pill for acromegaly that may replace the life-disrupting process of getting an injection every month or needing to follow a strict daily schedule for short-acting octreotide. Now in Phase 3, a once-daily oral therapy will be a welcome development for patients and could solve for a real market need. And there’s plenty more where that came from. Read on for our latest advancements and the market opportunities they hold for investment in our focused area of endocrinology pharmaceuticals.

Press Releases


CRN04777 DEMONSTRATES PHARMACOLOGIC PROOF-OF-CONCEPT WITH STRONG DOSE-DEPENDENT SUPPRESSION OF INSULIN SECRETION IN PHASE 1 SINGLE ASCENDING DOSE STUDY

Single-ascending dose cohorts of CRN04777 Phase 1 demonstrate proof-of-SST5 agonism and resultant inhibition of insulin secretion with CRN04777 exposure in healthy volunteers

Crinetics Pharmaceuticals to Participate in September Investor Conferences

Crinetics Pharmaceuticals management will participate in three investor conferences in September hosted by H.C. Wainwright, SVB Leerink and Cantor Fitzgerald. Live and archived webcasts will be available.

Corporate Presentation

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Contact


Contact